NEW YORK, January 31, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com takes a closer look at some Drug Manufacturers equities to see how they have
fared at the close. Lined up for review today are: Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), DURECT
Corp. (NASDAQ: DRRX), and Orexigen Therapeutics Inc. (NASDAQ: OREX). These companies are part of the Healthcare sector which was
moderately lower late Monday, January 30th, 2017, with the NYSE Health Care Index
dropping about 0.5%, while shares of health care companies in the S&P 500 were down almost 0.6% as a group. Learn more about
these stocks by downloading their comprehensive and free reports at:
http://stock-callers.com/registration
Depomed
Shares in Newark, California headquartered Depomed Inc. saw a drop of 1.22%, ending Monday's
trading session at $17.74. The stock recorded a trading volume of 644,118 shares. The Company's
shares are trading 7.09% below their 50-day moving average. Moreover, shares of Depomed, which engages in the development, sale,
and licensing of products for pain and other central nervous system conditions in the US, has a Relative Strength Index (RSI) of
40.92. DEPO complete research report is just a click away and free at:
http://stock-callers.com/registration/?symbol=DEPO
United Therapeutics
Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock declined 1.70%,
closing the day at $159.67 with a total trading volume of 520,989 shares. The Company's shares have
advanced 11.68% in the last one month, 37.24% in the previous three months, and 11.32% on an YTD basis. The stock is trading
12.96% above its 50-day moving average and 29.94% above its 200-day moving average. Additionally, shares of United Therapeutics,
which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening
diseases worldwide, have an RSI of 66.31.
On January 19th, 2017, research firm Standpoint Research downgraded the Company's
stock rating from 'Buy' to 'Hold'. The complimentary report on UTHR can be downloaded at:
http://stock-callers.com/registration/?symbol=UTHR
DURECT
On Monday, shares in Cupertino, California headquartered DURECT Corp. recorded a trading
volume of 1.32 million shares, which was higher than their three months average volume of 544,970 shares. The stock ended the day
9.32% lower at $1.07. The Company's shares are trading below their 50-day moving average by 17.44%.
Furthermore, shares of DURECT, which researches and develops therapies based on its epigenomic regulator program and proprietary
drug delivery platforms, has an RSI of 29.55.
On January 30th, 2017, DURECT provided an update on the DUR-928 development program.
The Company's first patient trial utilizing DUR-928 was an open-label, single-ascending-dose safety and pharmacokinetic (PK)
Phase-1b trial in liver function impaired (NASH) patients and matched control subjects. This study was conducted in Australia in successive cohorts evaluating single-dose levels of orally administered DUR-928. DURECT stated
that an abstract for this study has been accepted and data from the study will be presented at the International Liver Congress™
2017 organized by the European Association for the Study of the Liver in Amsterdam, April 19th-23rd, 2017. Sign up for your complimentary research report on DRRX at:
http://stock-callers.com/registration/?symbol=DRRX
Orexigen Therapeutics
La Jolla, California headquartered Orexigen Therapeutics Inc.'s stock dropped 1.20%,
finishing yesterday's session at $3.30 with a total trading volume of 261,794 shares. The Company's
shares have advanced 92.98% in the last one month, 10.74% in the previous three months, and 89.66% since the start of this year.
The stock is trading above its 50-day moving average by 34.73%. Additionally, shares of Orexigen Therapeutics, which focuses on
the development of pharmaceutical products, have an RSI of 59.19.
On January 25th, 2017, Orexigen Therapeutics announced that Laboratorios
Farmacéuticos Rovi, S.A. has launched Mysimba in Spain. Mysimba is approved by the European
Medicines Agency for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2,
or ≥ 27 kg/m2 to < 30 kg/m2 in the presence of one or more weight-related co-morbidities. ROVI will market Mysimba as part of
their diversified pharmaceutical portfolio under the terms of Orexigen Therapeutics' distributorship agreement signed in
August 2016. Following a successful partnering process in 2016, Orexigen currently has
commercialization arrangements with five different partners covering 38 countries. Get free access to your research report on
OREX at:
http://stock-callers.com/registration/?symbol=OREX
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA